463 related articles for article (PubMed ID: 28158620)
1. Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor.
Schmidt K; Prakash TP; Donner AJ; Kinberger GA; Gaus HJ; Low A; Østergaard ME; Bell M; Swayze EE; Seth PP
Nucleic Acids Res; 2017 Mar; 45(5):2294-2306. PubMed ID: 28158620
[TBL] [Abstract][Full Text] [Related]
2. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
5. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
[TBL] [Abstract][Full Text] [Related]
8. Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.
Miller CM; Tanowitz M; Donner AJ; Prakash TP; Swayze EE; Harris EN; Seth PP
Nucleic Acid Ther; 2018 Jun; 28(3):119-127. PubMed ID: 29425080
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
10. Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry.
Husser C; Brink A; Zell M; Müller MB; Koller E; Schadt S
Anal Chem; 2017 Jun; 89(12):6821-6826. PubMed ID: 28520401
[TBL] [Abstract][Full Text] [Related]
11. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
12. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
Wang Y; Yu RZ; Henry S; Geary RS
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
[No Abstract] [Full Text] [Related]
14. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
[TBL] [Abstract][Full Text] [Related]
15. Effect of modular conjugation strategy for
Yamamoto T; Sawamura M; Terada C; Kashiwada K; Wada F; Yamayoshi A; Obika S; Harada-Shiba M
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):109-118. PubMed ID: 31617782
[TBL] [Abstract][Full Text] [Related]
16. Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.
Yamamoto T; Sawamura M; Wada F; Harada-Shiba M; Obika S
Bioorg Med Chem; 2016 Jan; 24(1):26-32. PubMed ID: 26678173
[TBL] [Abstract][Full Text] [Related]
17. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor.
Scharner J; Qi S; Rigo F; Bennett CF; Krainer AR
Mol Ther Nucleic Acids; 2019 Jun; 16():313-325. PubMed ID: 30965276
[TBL] [Abstract][Full Text] [Related]
18. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
[TBL] [Abstract][Full Text] [Related]
19. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]